Long‐term effects of omalizumab on peripheral blood cells and C‐reactive protein levels in patients with chronic spontaneous urticaria
Sign Up to like & getrecommendations! Published in 2019 at "Dermatologic Therapy"
DOI: 10.1111/dth.12966
Abstract: Omalizumab's mechanism of action is not well‐understood yet despite its strong therapeutic efficacy in chronic spontaneous urticaria (CSU). To determine the overall effect of omalizumab on peripheral blood cell counts and serum C‐reactive protein levels… read more here.
Keywords: 12th month; 3rd month; peripheral blood; baseline ... See more keywords
Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience
Sign Up to like & getrecommendations! Published in 2022 at "International Archives of Allergy and Immunology"
DOI: 10.1159/000526410
Abstract: Introduction: Data showing effectiveness of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) are limited. Methods: This is a single-center retrospective chart review of patients with EGPA treated with mepolizumab. Clinical, laboratory, functional parameters… read more here.
Keywords: month; mepolizumab; life; egpa ... See more keywords
Studies on the Quantification of Mutation Resistance to Specific Drug Therapy in Chronic Myeloid Leukemia patients
Sign Up to like & getrecommendations! Published in 2021 at "Research Journal of Pharmacy and Technology"
DOI: 10.52711/0974-360x.2021.00709
Abstract: Imatinib is a type of protein tyrosine kinase inhibitor which inhibits the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome i.e. the BCR-ABL tyrosine kinase, abnormality in CML patient. The aim of the study… read more here.
Keywords: 12th month; imatinib; resistance; 18th month ... See more keywords